APEN - Apollo Endosurgery, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.0300
0.0000 (0.00%)
As of 10:27AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.0300
Open3.0100
Bid3.0200 x 900
Ask3.1300 x 1000
Day's Range3.0100 - 3.0500
52 Week Range3.0100 - 9.2500
Volume2,660
Avg. Volume11,561
Market Cap66.425M
Beta (3Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-1.9320
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Trade prices are not sourced from all markets
  • Business Wire22 days ago

    Apollo Endosurgery Announces Completion of Patient Enrollment for the Multi-Center ESG Randomized Interventional Trial (MERIT)

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the final patient has been enrolled in the Multi-Center ESG Randomized Interventional Trial (MERIT). The US based, prospective randomized multi-center-controlled trial is evaluating the effectiveness of the endoscopic sleeve gastroplasty (“ESG”) procedure. ESG is an endoscopic minimally invasive weight loss procedure based on full-thickness endoscopic suturing using Apollo’s OverStitch™ device.

  • Business Wirelast month

    Apollo Endosurgery, Inc. to Present at the JMP Securities 2019 Life Sciences Conference

    Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today that company management is scheduled to present at the JMP Securities 2019 Life Sciences Conference being held June 19-20, 2019 at the St.

  • Business Wirelast month

    Apollo Endosurgery Announces US Labeling Update on the ORBERA® Intragastric Balloon System

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures announced today that it has received FDA approval for its proposed labeling updates for the ORBERA® Intragastric Balloon System. The goal of the labeling updates is to improve patient safety and these will take effect immediately. The labeling updates improve patient safety by providing further definition and guidance on the appropriate use of the ORBERA® Intragastric Balloon System and patient selection.

  • Volatility 101: Should Apollo Endosurgery (NASDAQ:APEN) Shares Have Dropped 48%?
    Simply Wall St.2 months ago

    Volatility 101: Should Apollo Endosurgery (NASDAQ:APEN) Shares Have Dropped 48%?

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...

  • Business Wire2 months ago

    Apollo Endosurgery Announces DDW 2019 Clinical Highlights

    Apollo Endosurgery, Inc. , a leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced highlights from DDW 2019 which took place from May 18th to May 21st in San Diego.

  • Business Wire2 months ago

    Apollo Endosurgery to Participate in Digestive Disease Week® 2019

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today its participation during Digestive Disease Week 2019 (“DDW”). Apollo’s OverStitch™ Endoscopic Suturing System and ORBERA® Intragastric Balloon, will be featured in 40 clinical presentations that demonstrate the effectiveness of OverStitch and ORBERA when used across a number of diverse clinical needs. Apollo will also feature Overstitch Sx, its latest endoscopic suturing device designed for compatibility with single-channel endoscopes with diameters ranging from 8.8mm to 9.8mm.

  • Business Wire2 months ago

    Apollo Endosurgery, Inc. Reports First Quarter 2019 Results

    Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET

  • Business Wire3 months ago

    Apollo Endosurgery, Inc. to Report First Quarter Results on May 2, 2019

    Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended March 31, 2019 on Thursday, May 2, 2019, after the U.S.

  • Apollo Endosurgery (APEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks3 months ago

    Apollo Endosurgery (APEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Apollo Endosurgery (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Did Apollo Endosurgery, Inc. (NASDAQ:APEN) Insiders Buy Up More Shares?
    Simply Wall St.3 months ago

    Did Apollo Endosurgery, Inc. (NASDAQ:APEN) Insiders Buy Up More Shares?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunatel...

  • Business Wire4 months ago

    Apollo Endosurgery Appoints John Barr to Board of Directors

    The Board of Directors of Apollo Endosurgery, Inc. (“Apollo”) (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that John Barr has been appointed to Apollo’s Board of Directors as an independent director, effective immediately. Mr. Barr will join 9 other directors, a majority of whom are independent under the rules and regulations of the United States Securities and Exchange Commission, and will serve as a member of the Audit and Nominating and Governance Committees. “John is a highly accomplished leader in the medical device field and an experienced board member who brings a wealth of executive leadership skills and experience to our board,” said Rich Meelia, Chairman of Apollo’s Board of Directors.

  • Business Wire4 months ago

    Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2018 Results

    Conference Call to Discuss Results Today at 7:30 a.m. CT / 8:30 a.m. ET

  • Business Wire4 months ago

    Apollo Endosurgery, Inc. to Report Fourth Quarter Results on March 18, 2019

    Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the fourth quarter ended December 31, 2018 on Monday, March 18, 2019, before the U.S.

  • Does Market Volatility Impact Apollo Endosurgery, Inc.’s (NASDAQ:APEN) Share Price?
    Simply Wall St.5 months ago

    Does Market Volatility Impact Apollo Endosurgery, Inc.’s (NASDAQ:APEN) Share Price?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you own shares in Apollo Endosurgery, Inc. (NASDAQ:APEN) thenRead More...

  • Business Wire5 months ago

    Apollo Endosurgery Announces Publication of Outcomes of Endoscopic Sleeve Gastroplasty (ESG) in 1,000 Consecutive Patients

    Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced the publication of Outcomes of Endoscopic Gastroplasty in 1,000 Consecutive Patients from a single center - King Saud University, Riyadh, Saudi Arabia featured in Gastrointestinal Endoscopy - https://doi.org/10.1016/j.gie.2018.12.012.

  • Apollo Endosurgery, Inc. (NASDAQ:APEN) Investors Are Paying Above The Intrinsic Value
    Simply Wall St.6 months ago

    Apollo Endosurgery, Inc. (NASDAQ:APEN) Investors Are Paying Above The Intrinsic Value

    In this article I am going to calculate the intrinsic value of Apollo Endosurgery, Inc. (NASDAQ:APEN) by taking the expected future cash flows and discounting them to their present value. Read More...

  • What does Apollo Endosurgery, Inc.’s (NASDAQ:APEN) Balance Sheet Tell Us About Its Future?
    Simply Wall St.7 months ago

    What does Apollo Endosurgery, Inc.’s (NASDAQ:APEN) Balance Sheet Tell Us About Its Future?

    Apollo Endosurgery, Inc. (NASDAQ:APEN) is a small-cap stock with a market capitalization of US$77m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...

  • Business Wire7 months ago

    Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc. (“ReShape”) (RSLS). The definitive transaction agreements were signed and closed simultaneously yesterday, December 17, 2018. This transaction will allow Apollo to focus all its efforts on growing the clinical adoption of its Endo-bariatric product offerings, which consists of its OverStitch Endoscopic Suturing Systems and the Orbera Intragastric Balloon technologies.

  • GlobeNewswire7 months ago

    Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire8 months ago

    Apollo Endosurgery Announces First Commercial Shipment of the OverStitch™ Sx Endoscopic Suturing System

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today the first commercial shipments of the OverStitch™ Sx Endoscopic Suturing System. Flexible endoscopic suturing using Apollo’s OverStitch™ Endoscopic Suturing System is now established as an important tool for both surgeons and gastroenterologists that enables a wide array of new endolumenally performed patient treatment options. The OverStitch Sx is designed for compatibility with single-channel endoscopes with diameters ranging from 8.8mm to 9.8mm, and therefore provides more physicians with access to the benefits of full-thickness flexible endoscopic suturing regardless of their hospital’s selection of endoscopic capital equipment or endoscope manufacturer.

  • Business Wire8 months ago

    Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Obesity Week 2018 Conference

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced its participation during Obesity Week 2018 taking place November 11-15, 2018 at The Music City Center in Nashville, Tennessee. During the conference, Obesity Week will host several hands-on workshops including sessions that feature ORBERA® and OverStitch™ technologies. In addition the Apollo Mobile Learning Center will be in Nashville to support a series of hands-on physician training sessions.

  • Business Wire8 months ago

    Apollo Endosurgery, Inc. Reports Third Quarter 2018 Results

    Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET

  • Business Wire8 months ago

    Apollo Endosurgery, Inc. to Report Third Quarter Results on November 8, 2018

    Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2018 on Thursday, November 8, 2018, after the U.S.

  • Business Wire9 months ago

    Apollo Endosurgery Announces Distribution Agreement with Slater Endoscopy for the Ensizor® Flexible Endoscopic Scissors

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today that it has entered into an agreement with Slater Endoscopy, LLC to distribute the cold Ensizor® Flexible Endoscopic Scissors in the United States, Europe, and select other markets. The Ensizor Flexible Endoscopic Scissor is indicated to cut and dissect tissue and sutures during endoscopic procedures. The rigid armature provides unparalleled strength while the flexible blades ensure constant cutting contact providing physicians reliable and consistent cutting performance.